BACKGROUND: Advances in cancer treatments continue to reduce the incidence of lymphedema. Yet, many breast cancer survivors still face long-term postoperative challenges as a result of developing lymphedema. The purpose of this study was to preliminarily evaluate The Optimal Lymph Flow program, a patient-centered education and behavioral program focusing on self-care strategies to enhance lymphedema risk reduction by promoting lymph flow and optimize body mass index (BMI). METHODS: A prospective, longitudinal, quasi-experimental design with repeated-measures was used. The study outcomes included lymph volume changes by infrared perometer, and BMI by a bioimpedance device at pre-surgery baseline, 2-4 weeks after surgery, 6-month and 12-month follow-up. A total of 140 patients were recruited and participated in The Optimal Lymph Flow program; 134 patients completed the study with 4 % attrition rate. RESULTS: Fifty-eight percent of patients had axillary node dissection and 42 % had sentinel lymph node biopsy (SLNB). The majority (97 %) of patients maintained and improved their preoperative limb volume (LV) and BMI at the study endpoint of 12 months following cancer surgery. Cumulatively, two patients with SLNB and two patients with axillary lymph node dissection had measurable lymphedema (>10 % LV change). At the 12-month follow-up, among the four patients with measurable lymphedema, two patients' LV returned to preoperative level without compression therapy but by maintaining The Optimal Lymph Flow exercises to promote daily lymph flow. CONCLUSIONS: This educational and behavioral program is effective in enhancing lymphedema risk reduction. The study provided initial evidence for emerging change in lymphedema care from treatment-focus to proactive risk reduction.
BACKGROUND: Advances in cancer treatments continue to reduce the incidence of lymphedema. Yet, many breast cancer survivors still face long-term postoperative challenges as a result of developing lymphedema. The purpose of this study was to preliminarily evaluate The Optimal Lymph Flow program, a patient-centered education and behavioral program focusing on self-care strategies to enhance lymphedema risk reduction by promoting lymph flow and optimize body mass index (BMI). METHODS: A prospective, longitudinal, quasi-experimental design with repeated-measures was used. The study outcomes included lymph volume changes by infrared perometer, and BMI by a bioimpedance device at pre-surgery baseline, 2-4 weeks after surgery, 6-month and 12-month follow-up. A total of 140 patients were recruited and participated in The Optimal Lymph Flow program; 134 patients completed the study with 4 % attrition rate. RESULTS: Fifty-eight percent of patients had axillary node dissection and 42 % had sentinel lymph node biopsy (SLNB). The majority (97 %) of patients maintained and improved their preoperative limb volume (LV) and BMI at the study endpoint of 12 months following cancer surgery. Cumulatively, two patients with SLNB and two patients with axillary lymph node dissection had measurable lymphedema (>10 % LV change). At the 12-month follow-up, among the four patients with measurable lymphedema, two patients' LV returned to preoperative level without compression therapy but by maintaining The Optimal Lymph Flow exercises to promote daily lymph flow. CONCLUSIONS: This educational and behavioral program is effective in enhancing lymphedema risk reduction. The study provided initial evidence for emerging change in lymphedema care from treatment-focus to proactive risk reduction.
Authors: Marilyn L Kwan; Jeanne Darbinian; Kathryn H Schmitz; Rebecca Citron; Paula Partee; Susan E Kutner; Lawrence H Kushi Journal: Arch Surg Date: 2010-11
Authors: Bonnie B Lasinski; Kathryn McKillip Thrift; Decourcy Squire; Melanie K Austin; Kandis M Smith; Ausanee Wanchai; Jason M Green; Bob R Stewart; Janice N Cormier; Jane M Armer Journal: PM R Date: 2012-08 Impact factor: 2.298
Authors: Nicole L Stout; Jill M Binkley; Kathryn H Schmitz; Kimberly Andrews; Sandra C Hayes; Kristin L Campbell; Margaret L McNeely; Peter W Soballe; Ann M Berger; Andrea L Cheville; Carol Fabian; Lynn H Gerber; Susan R Harris; Karin Johansson; Andrea L Pusic; Robert G Prosnitz; Robert A Smith Journal: Cancer Date: 2012-04-15 Impact factor: 6.860
Authors: Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Gladys L Giron; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee Journal: J Clin Oncol Date: 2008-10-06 Impact factor: 44.544
Authors: So Shan Mak; Winnie Yeo; Yik Mun Lee; Kwok Fai Mo; Ka Yin Tse; Sut Mun Tse; Fung Ping Ho; Wing Hong Kwan Journal: Nurs Res Date: 2008 Nov-Dec Impact factor: 2.381
Authors: Mei R Fu; Yvette P Conley; Deborah Axelrod; Amber A Guth; Gary Yu; Jason Fletcher; David Zagzag Journal: Breast Date: 2016-07-22 Impact factor: 4.380
Authors: Mei R Fu; Deborah Axelrod; Amber A Guth; Kavita Rampertaap; Nardin El-Shammaa; Karen Hiotis; Joan Scagliola; Gary Yu; Yao Wang Journal: Mhealth Date: 2016-07-22
Authors: Mei R Fu; Yao Wang; Chenge Li; Zeyuan Qiu; Deborah Axelrod; Amber A Guth; Joan Scagliola; Yvette Conley; Bradley E Aouizerat; Jeanna M Qiu; Gary Yu; Janet H Van Cleave; Judith Haber; Ying Kuen Cheung Journal: Mhealth Date: 2018-05-29
Authors: Jae Hyung Park; John Merriman; Abraham Brody; Jason Fletcher; Gary Yu; Eunjung Ko; Alejandra Yancey; Mei R Fu Journal: Lymphat Res Biol Date: 2020-11-13 Impact factor: 2.349
Authors: Mei R Fu; Bradley E Aouizerat; Gary Yu; Yvette Conley; Deborah Axelrod; Amber A Guth; Jean-Pierre Gagner; Jeanna M Qiu; David Zagzag Journal: Curr Breast Cancer Rep Date: 2020-11-24